Get the Stockscreener App
223.85
1.78%
3.91
After Hours:
223.85
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $223.85, with a volume of 1.09M.
It is up +1.78% in the last 24 hours and down -4.14% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$219.94
Open:
$219.11
24h Volume:
1.09M
Relative Volume:
1.27
Market Cap:
$32.94B
Revenue:
$4.93B
Net Income/Loss:
$1.25B
P/E Ratio:
26.43
EPS:
8.47
Net Cash Flow:
$1.38B
1W Performance:
+0.42%
1M Performance:
-4.14%
6M Performance:
-8.30%
1Y Performance:
+13.04%
1-Day Range:
$215.05
$225.25
1-Week Range:
$215.05
$227.00
52-Week Range:
$172.19
$263.05
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
223.85 | 32.94B | 4.93B | 1.25B | 1.38B | 8.47 |
|
ISRG
Intuitive Surgical Inc
|
495.27 | 181.97B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
229.06 | 66.11B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
94.93 | 46.83B | 9.91B | 1.02B | 665.00M | 2.05 |
|
BAX
Baxter International Inc
|
34.23 | 17.65B | 17.28B | 108.00M | 391.00M | 0.20 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
Jim Cramer On ResMed Inc. (RMD) – “I’m With Mick! ResMed’s Doing Quite Well” - Insider Monkey
ResMed Inc. (NYSE:RMD) is a favorite amongst institutional investors who own 72% - simplywall.st
Solid sales from ASX healthcare leader - Morningstar.com.au
Is ResMed Stock Outperforming the Dow? - Nasdaq
ResMed initiated with an Overweight at Morgan Stanley - Yahoo Finance
Is ResMed Stock Outperforming The Dow? - Barchart
Resmed Says CPAP Therapy Reduces Risk Of Death By 37% In Sleep Apnea Patients - Nasdaq
Resmed’s Brand Evolution - Sleep Review
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
Why Breville, Flight Centre, Orica, and ResMed shares are dropping today - MSN
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare And Medtronic - Barchart
The Zacks Analyst Blog Highlights NVIDIA, Resmed, GE HealthCare and Medtronic - Yahoo Finance
Why APA, Aurelia Metals, Magnetic Resources, and ResMed shares are rising today - MSN
ResMed’s chief commercial officer sells $2.33 million in stock By Investing.com - Investing.com Australia
Should you buy this top ASX share in the dip? - MSN
Resmed to Consolidate Portfolio into One Brand; Shares Fall 5% -March 12, 2025 at 12:33 am EDT - Marketscreener.com
ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $230,360 in company stock By Investing.com - Investing.com South Africa
ResMed CFO Brett Sandercock sells $230,360 in company stock - Investing.com India
Resmed Chief Commercial Officer Offloads $2.3 Million Worth of Shares -March 11, 2025 at 06:27 pm EDT - Marketscreener.com
Resmed Inc Announces Proposed Sale of Securities - TipRanks
ResMed Inc. CEO Reports Stock Transactions Under Rule 10b5-1 Plan - TipRanks
ResMed’s chief commercial officer sells $2.33 million in stock - Investing.com
Resmed unveils unified brand to streamline services - MassDevice
ResMed CEO Michael J. Farrell sells $1.84 million in stock - Investing.com India
Resmed Unveils Unified Brand To Lead The Global Sleep And Health Technology Revolution - Marketscreener.com
Resmed Unveils Unified Brand to Lead the Global Sleep and Health Technology Revolution - The Korea Bizwire
Resmed Consolidating Brands, Product Lines Under Single Name -March 11, 2025 at 09:25 am EDT - Marketscreener.com
Resmed Unveils Comprehensive Brand Evolution to Enhance Global Sleep and Breathing Health Engagement - Nasdaq
Respiratory Inhalers Market to Witness Remarkable Growth with ResMed Inc., Fisher & Paykel Healthcare, Medtronic - openPR
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD) - Yahoo Finance
ResMed Shows Market Leadership With Jump To 81 RS Rating - Investor's Business Daily
Jones Financial Companies Lllp Grows Stock Holdings in ResMed Inc. (NYSE:RMD) - Defense World
Brokers rate these 2 ASX growth stocks as top buys - MSN
ResMed Inc Officer Plans Sale of Common Shares - TipRanks
ResMed Among Top Stocks For Recent And Long-Term Profit Growth - Investor's Business Daily
ResMed Insiders Sold US$12m Of Shares Suggesting Hesitancy - Simply Wall St
ResMed (NYSE:RMD) Cut to “Hold” at StockNews.com - Defense World
Citi slaps buy rating on ResMed shares - MSN
Is it Worth Adding ResMed Stock to Your Portfolio Now? - MSN
ResMed (NYSE:RMD) Raised to “Buy” at Citigroup - Defense World
Stifel Nicolaus Issues Pessimistic Forecast for ResMed (NYSE:RMD) Stock Price - Defense World
Europe Sleep Apnea Devices Analysis Report 2025: Market Set - GlobeNewswire
Europe Sleep Apnea Devices Analysis Report 2025: Market Set for Notable Growth, Reaching $3.77 Billion by 2033 with Natus Medical, ResMed, and Koninklijke Philips Leading - Yahoo Finance
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.88%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):